Your browser doesn't support javascript.
loading
Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.
Autmizguine, Julie; Melloni, Chiara; Hornik, Christoph P; Dallefeld, Samantha; Harper, Barrie; Yogev, Ram; Sullivan, Janice E; Atz, Andrew M; Al-Uzri, Amira; Mendley, Susan; Poindexter, Brenda; Mitchell, Jeff; Lewandowski, Andrew; Delmore, Paula; Cohen-Wolkowiez, Michael; Gonzalez, Daniel.
Afiliação
  • Autmizguine J; Research Center, CHU Sainte-Justine, and Department of Pharmacology and Physiology, Université de Montréal, Montreal, Quebec, Canada.
  • Melloni C; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Hornik CP; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Dallefeld S; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Harper B; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Yogev R; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Sullivan JE; University of Louisville, Norton Children's Hospital and Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, USA.
  • Atz AM; Medical University of South Carolina, Charleston, South Carolina, USA.
  • Al-Uzri A; Oregon Health and Science University, Portland, Oregon, USA.
  • Mendley S; University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Poindexter B; Perinatal Institute, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
  • Mitchell J; Emmes Corporation, Rockville, Maryland, USA.
  • Lewandowski A; Emmes Corporation, Rockville, Maryland, USA.
  • Delmore P; Wesley Medical Center, Wichita, Kansas, USA.
  • Cohen-Wolkowiez M; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Gonzalez D; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA daniel.gonzalez@unc.edu.
Article em En | MEDLINE | ID: mdl-29084742
Trimethoprim (TMP)-sulfamethoxazole (SMX) is used to treat various types of infections, including community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) and Pneumocystis jirovecii infections in children. Pharmacokinetic (PK) data for infants and children are limited, and the optimal dosing is not known. We performed a multicenter, prospective PK study of TMP-SMX in infants and children. Separate population PK models were developed for TMP and SMX administered by the enteral route using nonlinear mixed-effects modeling. Optimal dosing was determined on the basis of the matching adult TMP exposure and attainment of the surrogate pharmacodynamic (PD) target for efficacy, a free TMP concentration above the MIC over 50% of the dosing interval. Data for a total of 153 subjects (240 samples for PK analysis) with a median postnatal age of 8 years (range, 0.1 to 20 years) contributed to the analysis for both drugs. A one-compartment model with first-order absorption and elimination characterized the TMP and SMX PK data well. Weight was included in the base model for clearance (CL/F) and volume of distribution (V/F). Both TMP and SMX CL/F increased with age. In addition, TMP and SMX CL/F were inversely related to the serum creatinine and albumin concentrations, respectively. The exposure achieved in children after oral administration of TMP-SMX at 8/40 mg/kg of body weight/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 320/1,600 mg/day divided into administration every 12 h and achieved the PD target for bacteria with an MIC of 0.5 mg/liter in >90% of infants and children. The exposure achieved in children after oral administration of TMP-SMX at 12/60 and 15/75 mg/kg/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 640/3,200 mg/day divided into administration every 12 h in subjects 6 to <21 years and 0 to <6 years of age, respectively, and was optimal for bacteria with an MIC of up to 1 mg/liter.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Combinação Trimetoprima e Sulfametoxazol / Antibacterianos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Combinação Trimetoprima e Sulfametoxazol / Antibacterianos Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2018 Tipo de documento: Article